(NRIX) Nurix Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.640m USD | Total Return: 75.2% in 12m
Avg Turnover: 14.9M
Qual. Beats: 0
Rev. Trend: 31.1%
Qual. Beats: 0
Warnings
Share dilution 31.7% YoY
Interest Coverage Ratio -3.9 is critical
Altman Z'' -11.58 < 1.0 - financial distress zone
Extended 3d
Tailwinds
Confidence
Nurix Therapeutics, Inc. (NRIX) is a clinical-stage biopharmaceutical company focused on small molecule and antibody therapies. The company utilizes a targeted protein modulation platform to develop degraders and inhibitors for cancer, autoimmune disorders, and inflammatory diseases. Its lead candidates include NX-5948 and NX-2127, which target Brutons tyrosine kinase (BTK) for B-cell malignancies, and NX-1607, a CBL-B inhibitor for immuno-oncology.
The company operates within the biotechnology sector, where high research and development costs are often offset by strategic partnerships. Nurix maintains significant collaboration agreements with major pharmaceutical entities, including Gilead Sciences, Sanofi, and Pfizer, to co-develop and co-commercialize multiple drug candidates. This business model leverages external capital and infrastructure to advance early-stage clinical trials through the regulatory pipeline.
Investors can find further data-driven insights on these clinical developments by exploring ValueRay.
- Phase 2 clinical data for NX-5948 determines long-term valuation in B-cell malignancies
- Collaboration milestones from Gilead and Sanofi provide essential non-dilutive capital
- Regulatory progress of NX-2127 influences competitive standing against established BTK inhibitors
- Clinical trial enrollment speed impacts cash burn and future financing requirements
- Expansion into autoimmune indications diversifies revenue potential beyond core oncology markets
| Net Income: -295.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.43 > 0.02 and ΔFCF/TA -9.96 > 1.0 |
| NWC/Revenue: 643.9% < 20% (prev 839.7%; Δ -195.8% < -1%) |
| CFO/TA -0.41 > 3% & CFO -260.3m > Net Income -295.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.1m) vs 12m ago 31.73% < -2% |
| Gross Margin: -139.4% > 18% (prev -3.28%; Δ -13.6k% > 0.5%) |
| Asset Turnover: 11.47% > 50% (prev 9.17%; Δ 2.30% > 0%) |
| Interest Coverage Ratio: -3.87 > 6 (EBITDA TTM -296.8m / Interest Expense TTM 81.6m) |
| A: 0.73 (Total Current Assets 554.4m - Total Current Liabilities 92.2m) / Total Assets 636.1m |
| B: -1.71 (Retained Earnings -1.09b / Total Assets 636.1m) |
| C: -0.50 (EBIT TTM -315.3m / Avg Total Assets 625.6m) |
| D: -7.02 (Book Value of Equity -1.09b / Total Liabilities 155.2m) |
| Altman-Z'' = -11.58 = D |
| DSRI: 0.21 (Receivables 2.40m/9.10m, Revenue 71.8m/56.4m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.24 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.27 (Revenue 71.8m / 56.4m) |
| TATA: -0.06 (NI -295.3m - CFO -260.3m) / TA 636.1m) |
| Beneish M = -3.40 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 17.53 with a total of 1,288,377 shares traded.
Over the past week, the price has changed by +10.38%,
over one month by +5.23%,
over three months by +13.78% and
over the past year by +75.18%.
Nurix Therapeutics has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy NRIX.
- StrongBuy: 10
- Buy: 6
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30.2 | 72.2% |
P/B = 3.5544
Revenue TTM = 71.8m USD
EBIT TTM = -315.3m USD
EBITDA TTM = -296.8m USD
Long Term Debt = 55.5m USD (estimated: total debt 58.7m - short term 3.20m)
Short Term Debt = 3.20m USD (from shortTermDebt, last quarter)
Debt = 58.7m USD (from shortLongTermDebtTotal, last quarter) (leases 58.7m already included)
Net Debt = -482.1m USD (calculated: Debt 58.7m - CCE 540.7m)
Enterprise Value = 1.16b USD (1.64b + Debt 58.7m - CCE 540.7m)
Interest Coverage Ratio = -3.87 (Ebit TTM -315.3m / Interest Expense TTM 81.6m)
EV/FCF = -4.26x (Enterprise Value 1.16b / FCF TTM -271.9m)
FCF Yield = -23.49% (FCF TTM -271.9m / Enterprise Value 1.16b)
FCF Margin = -378.7% (FCF TTM -271.9m / Revenue TTM 71.8m)
Net Margin = -411.4% (Net Income TTM -295.3m / Revenue TTM 71.8m)
Gross Margin = -139.4% ((Revenue TTM 71.8m - Cost of Revenue TTM 171.9m) / Revenue TTM)
Gross Margin QoQ = none% (prev 65.89%)
Tobins Q-Ratio = 1.82 (Enterprise Value 1.16b / Total Assets 636.1m)
Interest Expense / Debt = 139.0% (Interest Expense 81.6m / Debt 58.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -249.1m (EBIT -315.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.01 (Total Current Assets 554.4m / Total Current Liabilities 92.2m)
Debt / Equity = 0.12 (Debt 58.7m / totalStockholderEquity, last quarter 480.9m)
Debt / EBITDA = 1.62 (negative EBITDA) (Net Debt -482.1m / EBITDA -296.8m)
Debt / FCF = 1.77 (negative FCF - burning cash) (Net Debt -482.1m / FCF TTM -271.9m)
Total Stockholder Equity = 459.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.20% (Net Income -295.3m / Total Assets 636.1m)
RoE = -19.05% (Net Income TTM -295.3m / Total Stockholder Equity 1.55b)
RoCE = -19.64% (EBIT -315.3m / Capital Employed (Equity 1.55b + L.T.Debt 55.5m))
RoIC = -46.57% (negative operating profit) (NOPAT -249.1m / Invested Capital 534.8m)
WACC = 10.17% (E(1.64b)/V(1.70b) * Re(10.53%) + (debt cost/tax rate unavailable))
Discount Rate = 10.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 36.48%
[DCF] Fair Price = unknown (Cash Flow -271.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.31 | # QB: 0
Revenue Correlation: 31.06 | Revenue CAGR: 6.22% | SUE: -0.71 | # QB: 0
EPS current Quarter (2026-05-31): EPS=-0.71 | Chg30d=+0.54% | Revisions=+71% | Analysts=15
EPS next Quarter (2026-08-31): EPS=-0.74 | Chg30d=+0.37% | Revisions=+60% | Analysts=15
EPS current Year (2026-11-30): EPS=-2.95 | Chg30d=-0.34% | Revisions=+22% | GrowthEPS=+3.4% | GrowthRev=-36.7%
EPS next Year (2027-11-30): EPS=-2.86 | Chg30d=-0.10% | Revisions=+47% | GrowthEPS=+2.8% | GrowthRev=+39.4%
[Analyst] Revisions Ratio: +71%